10-Q: Nurix Therapeutics Reports Q3 2025 Amid R&D Surge

Nurix Therapeutics reported increased net losses in Q3 2025 driven by accelerated R&D spending on its clinical pipeline, while securing significant license revenue from Sanofi.

Summary

• Net loss for the nine months ended August 31, 2025, increased to $186.2 million from $135.0 million in the prior year.
• Total revenue for the nine months ended August 31, 2025, increased to $70.4 million from $41.3 million, primarily due to $30.0 million in license revenue from Sanofi.
• Research and development (R&D) expenses surged by $79.5 million to $233.9 million for the nine months ended August 31, 2025, reflecting accelerated clinical trial enrollment and increased contract manufacturing costs.
• Cash, cash equivalents, and marketable securities stood at $428.8 million as of August 31, 2025, down from $526.9 million as of November 30, 2024.
• The company expects existing cash to fund operations for at least the next 12 months but will require substantial additional funding for long-term plans.
• Key clinical programs, bexobrutideg (NX-5948), zelebrudomide (NX-2127), and NX-1607, are advancing, with bexobrutideg expected to initiate a Phase 2 clinical trial in 2025.
• Sanofi exercised options to exclusively license two targets, triggering $30.0 million in license extension fees.
• The company continues to leverage its DEL-AI platform for drug discovery and has potential future milestone payments of up to $6.1 billion from collaborations.

Sentiment

Score: 4

Explanation: While Nurix Therapeutics achieved a significant license revenue milestone and advanced its clinical pipeline with positive regulatory designations, the substantial increase in net loss and R&D expenses, coupled with a decrease in cash and marketable securities, indicates a worsening financial burn rate. The explicit need for substantial additional funding beyond the next 12 months highlights ongoing financial challenges despite clinical progress.

Positives

• Significant license revenue of $30.0 million received from Sanofi due to the exercise of exclusive licensing options for two targets.
• Bexobrutideg (NX-5948) received Fast Track designation from the FDA for relapsed or refractory CLL/SLL and Waldenström macroglobulinemia.
• Bexobrutideg also received PRIME designation from the EMA for CLL/SLL and Orphan Drug Designation from the FDA for WM and from the EMA for lymphoplasmacytic lymphoma.
• Anticipated initiation of a Phase 2 clinical trial for bexobrutideg in 2025.
• Reinitiated enrollment for zelebrudomide (NX-2127) Phase 1a/1b study after the FDA lifted a partial clinical hold.
• NX-1607 was awarded an Innovation Passport from the UK MHRA to accelerate time to market.
• Eligibility to receive up to approximately $6.1 billion in total additional payments from collaborations with Gilead, Sanofi, and Pfizer, plus royalties on future product sales.
• Cash, cash equivalents, and marketable securities of $428.8 million are believed to be sufficient for at least the next 12 months of operating activities.

Negatives

• Net loss significantly increased to $186.2 million for the nine months ended August 31, 2025, compared to $135.0 million for the same period in 2024.
• Cash, cash equivalents, and marketable securities decreased to $428.8 million as of August 31, 2025, from $526.9 million as of November 30, 2024.
• Collaboration revenue decreased by $4.7 million for the three months ended August 31, 2025, and by $0.9 million for the nine months ended August 31, 2025, primarily due to the conclusion of initial research terms for certain drug targets with Sanofi and Gilead.
• Research and development expenses increased substantially by $79.5 million to $233.9 million for the nine months ended August 31, 2025, indicating a higher burn rate.
• Accumulated deficit reached $925.0 million as of August 31, 2025.
• The company will need substantial additional funding beyond the next 12 months to complete clinical trials and commercialization.
• The FDA previously placed a partial clinical hold on the zelebrudomide (NX-2127) study in October 2023, which was only lifted in March 2024, causing delays.

Risks

• Incurred significant losses since inception and expects to incur losses for at least the next several years, may never achieve or maintain profitability.
• Never generated revenue from product sales and may never be profitable.
• Will need substantial additional funding; inability to raise capital when needed may require delaying, limiting, reducing, or terminating research or product development programs or future commercialization efforts.
• Current and future legislation may increase the difficulty and cost for obtaining marketing approval and commercializing drug candidates, affecting prices.
• Early stage of development for lead drug candidates (bexobrutideg, zelebrudomide, NX-1607); inability to advance through clinical development or obtain regulatory approval could materially harm the business.
• Limited operating history makes it difficult to evaluate success and future viability.
• Serious adverse events, undesirable side effects, or unexpected characteristics identified during development may lead to abandonment or limitation of clinical development.
• Results of preclinical studies and early-stage clinical trials may not be predictive of future results; initial success may not be indicative of later-stage trials.
• Unsuccessful in obtaining or maintaining Orphan Drug Designation or other designations, or unable to maintain associated benefits.
• Drug candidates may fail to obtain regulatory data protection or extension if not considered new active substance, fall within global marketing authorization of existing product, or if pediatric studies are not adequately completed.
• Substantial competition in an environment of rapid technological change, potentially leading to others developing or commercializing products more successfully.
• Dependence on collaborations with third parties; if unsuccessful, unable to capitalize on market potential.
• Reliance on third-party contract manufacturing organizations (CMOs) increases risk of insufficient quantities, unacceptable cost/quality, delaying or impairing development/commercialization.
• Inability to obtain and maintain broad patent protection for technology and drug candidates, allowing competitors to develop similar products.
• Risk of not identifying relevant third-party patents or incorrectly interpreting their relevance, scope, or expiration, leading to infringement allegations.
• Unfavorable global economic conditions could adversely affect business, financial condition, stock price, and results of operations.
• Failure to attract and retain management and other key personnel could hinder successful development and commercialization.
• Even if commercialized, products may be subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, or fail to secure positive health technology assessment.
• Biopharmaceutical industry subject to extensive regulatory obligations and policies that are subject to change, including due to judicial challenges (e.g., U.S. Supreme Court decision on agency deference).
• Manufacturing of drugs is complex, and the company/third-party manufacturers are early in efforts, potentially leading to production difficulties.
• Estimated market opportunities for drug candidates are subject to numerous uncertainties and may prove inaccurate.
• Product liability lawsuits could cause substantial liabilities and limit commercialization.
• Inability to protect confidentiality of trade secrets would harm business and competitive position.
• Intellectual property rights do not necessarily address all potential threats.
• Inability to pursue or guarantee protection of intellectual property rights in jurisdictions outside the United States.
• Obtaining and maintaining patent protection depends on compliance with various procedural, documentary, fee payment, and other requirements.
• Subject to claims challenging inventorship or ownership of patents and other intellectual property.
• Involvement in lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• UK's exit from the EU creates political and economic uncertainty, impacting regulatory activities and market access.
• Disruptions at the FDA may slow review/approval times.
• Governments outside the U.S. tend to impose strict price controls.
• Dependence on information technology systems; security breaches, cyber-attacks, loss of data could harm business.
• Use of artificial intelligence (DEL-AI platform) presents risks related to accuracy, bias, cybersecurity, and evolving regulation.
• U.S. federal income tax reform and changes in other tax laws could adversely affect the company (e.g., R&E expense capitalization, IRA drug pricing).
• Ability to utilize net operating loss carryforwards may be subject to limitations (Sections 382 and 383 of the Code).
• Future acquisitions, joint ventures, spin-outs, or strategic alliances could disrupt business.
• Subject to anti-corruption laws, export control laws, customs laws, sanctions laws, and other laws governing operations.
• Failure to comply with environmental, health, and safety laws could lead to fines or penalties.
• Operations in San Francisco Bay Area exposed to earthquakes or other natural disasters.
• Stock price volatility.
• Future sale and issuance of equity or convertible debt will dilute share capital.
• Will not receive significant funds from pre-funded warrant exercise, but exercise increases shares eligible for resale, causing dilution.
• No public market for pre-funded warrants.
• Anti-takeover provisions in charter documents and under Delaware law could make an acquisition more difficult and may prevent attempts by stockholders to replace or remove current management.
• Exclusive forum provisions for certain claims could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Will continue to incur increased costs as a result of operating as a public company, and management will be required to devote substantial time to new compliance initiatives and corporate governance practices.
• Failure to maintain effective internal control over financial reporting could impair ability to produce accurate and timely financial statements.
• Do not anticipate paying any cash dividends on capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain.
• May be subject to securities litigation, which is expensive and could divert management attention.

Future Outlook

The company expects to incur losses over at least the next several years and may never achieve or maintain profitability, anticipating additional losses until significant sales of drug candidates are generated. Expenses are projected to increase substantially as drug candidates advance through preclinical and clinical development, external manufacturing scales up, the DEL-AI platform expands, marketing approvals are sought, commercial infrastructure is established, intellectual property is protected, and personnel are hired. Interest income is expected to fluctuate based on balances and market rates. Substantial additional funding will be required beyond the next 12 months to support continuing operations and long-term business plans, with future capital requirements dependent on R&D spending and collaboration payments. Starting with the tax year ending November 30, 2026, the company will no longer be required to capitalize domestic research and experimental costs under Section 174 of the Internal Revenue Code.

Management Comments

• We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the degradation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions and other challenging diseases.
• Leveraging the Company's expertise in E3 ligases together with its proprietary DNA-encoded libraries, the Company has built DEL-AI, a fully AI-integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can degrade proteins within the cell.
• We aim to establish degrader-based treatments at the forefront of patient care, writing medicine's next chapter with a new script to outmatch disease.
• Management believes that its cash, cash equivalents and marketable securities are sufficient to continue operating activities for at least 12 months following the issuance date of these condensed financial statements.
• We expect our research and development expenses to increase for the foreseeable future as we conduct clinical trials for our drug candidates, continue to invest in research and development activities for discovery programs and preclinical studies, pursue regulatory approval of our drug candidates and expand our drug candidate pipeline.
• We expect our general and administrative expenses to increase for the foreseeable future as we continue to improve our infrastructure and operate as a public company.

Industry Context

The company operates in the highly competitive biopharmaceutical industry, characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. Targeted protein degradation is a new treatment modality with very few small molecule drug candidates tested in humans and none approved in the U.S. or Europe, indicating a nascent but high-potential field. The industry faces increasing financial market volatility, inflation, interest rate fluctuations, and potential government shutdowns, impacting business, clinical trials, and financial condition. The U.S. Supreme Court's recent opinion on agency deference (June 28, 2024) may increase challenges to FDA interpretations of law, potentially impacting regulatory policies and costs for the biopharmaceutical industry. The Inflation Reduction Act (IRA) and other legislative efforts aim to control drug pricing, potentially affecting future revenues and profitability. The UK's exit from the EU (Brexit) continues to create regulatory complexity and uncertainty for pharmaceutical product commercialization in Europe. The use of AI in drug discovery is an emerging trend, with competitors also incorporating AI, and evolving regulations around AI development and use.

Comparison to Industry Standards

• The company's lead candidate, bexobrutideg (NX-5948), targets chronic lymphocytic leukemia (CLL), a market where ibrutinib is a well-established treatment. Nurix aims to address patients with BTK inhibitor resistance, indicating a strategy to target unmet needs within an existing competitive landscape.
• The company highlights that 'Very few small molecule drug candidates designed to control cellular protein levels, such as our BTK degraders, have been tested in humans, none have been approved in the United States or Europe,' positioning its targeted protein degradation approach as novel and early-stage compared to more traditional therapeutic modalities.
• Nurix acknowledges that 'Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do,' indicating it operates as a smaller, specialized biotech firm against larger, more established pharmaceutical companies.
• The pursuit of Fast Track, PRIME, and Orphan Drug designations for its drug candidates aligns with common industry strategies for accelerating development and gaining market exclusivity for serious or rare diseases with high unmet medical needs.
• Collaborations with major pharmaceutical companies like Gilead, Sanofi, and Pfizer (formerly Seagen) are a standard industry practice for biotech firms to leverage their discovery platforms, share development risks, and access broader development and commercialization capabilities.

Corporate Governance

Legal Proceedings

• The company was not a party to any material legal proceedings as of August 31, 2025.
• The California Franchise Tax Board (FTB) initiated an examination of the company's California tax return for tax years ending in 2015, 2016, 2017, and 2018, issuing proposed audit assessments related to revenue sourcing and R&D credits. The company challenged these assessments, received new information in May 2025, remeasured the unrecognized tax benefit, and entered into settlement procedures with the FTB in September 2025.

Related Party Transactions

• The company's Chief Financial Officer is a trustee for the multiple employer welfare association that facilitates the acquisition and administration of the company's healthcare plans.
• Expenses related to the healthcare plan premiums were $4.6 million for the nine months ended August 31, 2025, compared to $3.2 million for the nine months ended August 31, 2024.

Stakeholder Impact

• Shareholders face potential for dilution from future equity offerings and stock price volatility due to clinical trial results, regulatory developments, competition, and financial performance. There is a risk of losing all or part of their investment due to significant losses and the need for additional funding.
• Employees benefit from increased headcount in R&D and G&A functions and stock-based compensation as a retention tool, but the company faces the risk of losing key personnel to competitors.
• Future patients could benefit from new treatments for cancer and autoimmune diseases (bexobrutideg, zelebrudomide, NX-1607), but face risks of undesirable side effects, lack of efficacy, or delayed access due to regulatory hurdles or manufacturing issues.
• Suppliers and vendors, particularly third-party Contract Manufacturing Organizations (CMOs), are critical for manufacturing, but reliance on them exposes the company to supply disruptions, quality issues, and increased costs.
• Creditors may view the increased accumulated deficit and ongoing losses as a concern, although the current cash position is deemed sufficient for the next 12 months.

Next Steps

• Initiate a Phase 2 clinical trial of bexobrutideg (NX-5948) in 2025.
• Initiate a Phase 1 healthy volunteer study for bexobrutideg to assess food effects and drug-drug interactions in anticipation of planned pivotal development in 2025.
• Continue to advance zelebrudomide (NX-2127) in Phase 1b expansion cohorts for relapsed CLL, diffuse large B-cell lymphoma, and mantle cell lymphoma.
• Continue conducting a Phase 1a/1b dose-escalation and cohort expansion study of NX-1607 in oncology indications, including a cohort with paclitaxel.
• Apply the DEL-AI platform to advance additional drug candidates and expand platform capabilities.
• Seek marketing approvals for any drug candidates that successfully complete clinical trials.
• Ultimately establish a sales, marketing, and distribution infrastructure and scale up external manufacturing capabilities to commercialize approved products.
• Expand, maintain, and protect the intellectual property portfolio.
• Hire additional clinical, regulatory, manufacturing, quality assurance, and scientific personnel.
• Continue to improve operational, financial, and management controls, reporting systems, and procedures as a public company.
• Negotiate and potentially enter into additional collaboration agreements.
• Address potential future tax liabilities, including those related to NOL carryforwards and R&E expenses.
• Implement new measures to comply with evolving data privacy and security laws.

Key Dates

Recommendation

Nurix Therapeutics is in a high-risk, high-reward stage. While the company has made notable clinical progress with multiple drug candidates receiving Fast Track, PRIME, and Orphan Drug designations, and secured significant license revenue, its financial performance shows a substantial increase in net losses and R&D expenses, leading to a higher cash burn. The explicit need for 'substantial additional funding' beyond the next 12 months, coupled with the inherent uncertainties of clinical development and regulatory approval, presents significant financial risk. The potential for multi-billion dollar milestone payments from collaborations offers long-term upside, but this is contingent on successful development. Given the current financial trajectory and the early stage of its pipeline, a 'hold' recommendation is appropriate for investors who are already invested and believe in the long-term potential of the DEL-AI platform and pipeline, but new investors should exercise caution due to the high burn rate and future funding requirements.

Keywords

Nurix Therapeutics, NRIX, biopharmaceutical, targeted protein degradation, DEL-AI platform, cancer, autoimmune diseases, bexobrutideg, NX-5948, zelebrudomide, NX-2127, NX-1607, BTK degrader, CBL-B inhibitor, clinical stage, Gilead Sciences, Sanofi, Pfizer, Seagen, Orphan Drug Designation, Fast Track designation, PRIME designation, clinical trials, drug development, biotechnology, oncology, inflammation, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, immuno-oncology, DACs, degrader antibody conjugates, E3 ligases, financial results, SEC filing, 10-Q